Nebenwirkungen · Xalkori
XALKORI 200 mg hard capsules XALKORI 250 mg hard capsules XALKORI 20 mg granules in capsules for opening XALKORI 50 mg granules in capsules for opening XALKORI 150 mg granules in capsules for opening · Abschnitt 4.8 · PDF-Seite 25
HOS-126349 · Präparat HOS-096239
Adult patients with NSCLC Across studies in adult patients with either ALK-positive or ROS1-positive advanced NSCLC (N=1722), Grade 3 or 4 neutropenia was observed in 212 (12%) patients treated with crizotinib. Median time to onset of any grade neutropenia was 89 days. Neutropenia was associated with dose reduction or permanent treatment discontinuation for 3% and <1% of patients, respectively. Less than 0.5% of patients experienced febrile neutropenia in clinical studies with crizotinib.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-17T11:44:00Z · SHA-256 ef70dd9e8f617f709767e5bd4c7044eb23893a7ac40281434ebfa2fb8fb4e3d5 · Passage 8a6d3d55923001eb92e9a7a89bdd618fba56bd2114eaa6e9e0fe06c825eda2fe · Zeichen 29921–30414 im Abschnitt